Polymer/magnetite carriers functionalized by HER2-DARPin: Avoiding lysosomes during internalization and controlled toxicity of doxorubicin by focused ultrasound induced release

Новоселова, М. В.; Шрамова, Е. И.; Sergeeva, Olga V.; Shcherbinina, E.Y.; Perevoschikov, Stanislav; Melnikov, Pavel; Gryaznova, O.Yu.; Sergeev, I.S.; Коновалова, Е. В.; Schulga, Alexey; Прошкина, Г. М.; Zatsepin, Timofei S.; Deyev, Sergey M.; Gorin, Dmitry A.

doi:10.1016/j.nano.2022.102612

Cited by 4 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The carboxyl groups of the dextran component have been used to covalently immobilize HER2-targeting DARPin molecules, and the resulting hybrids tested both in vitro on ovarian adenocarcinoma HER2-overexpressing SKOV-3 cells and in vivo on tumor-bearing BALB/c nude mice. The researchers demonstrated that these An alternative approach is shown by Novoselova et al who demonstrated the therapeutic effect of HER2-targeting nanocomposites on cancer cells upon remote release of cytostatic Dox by low-intensity focused ultrasound (LIFU) [60]. In this study, Dox and magnetite NPs have been encapsulated by freezing-induced loading before coating with a polymeric shell bearing a couple of bilayers made by polyarginine and dextran sulfate resulting in 400 nm NPs.…”

Section: Hybrid Nanomaterialsmentioning

confidence: 91%

“…It is important to recall that these nanocarriers are biodegradable under a tumor microenvironment while also providing a means to realize imaging for the tumor target cells, thus being very versatile affibody-driven nanotools for cancer theragnostics. An alternative approach is shown by Novoselova et al who demonstrated the therapeutic effect of HER2-targeting nanocomposites on cancer cells upon remote release of cytostatic Dox by low-intensity focused ultrasound (LIFU) [60]. In this study, Dox and magnetite NPs have been encapsulated by freezing-induced loading before coating with a polymeric shell bearing a couple of bilayers made by polyarginine and dextran sulfate resulting in 400 nm NPs.…”

Section: Hybrid Nanomaterialsmentioning

confidence: 98%

See 1 more Smart Citation

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy

Gabriele,

Palerma,

Ippoliti

et al. 2023

IJMS

View full text Add to dashboard Cite

Affibodies and designed ankyrin repeat proteins (DARPins) are synthetic proteins originally derived from the Staphylococcus aureus virulence factor protein A and the human ankyrin repeat proteins, respectively. The use of these molecules in healthcare has been recently proposed as they are endowed with biochemical and biophysical features heavily demanded to target and fight diseases, as they have a strong binding affinity, solubility, small size, multiple functionalization sites, biocompatibility, and are easy to produce; furthermore, impressive chemical and thermal stability can be achieved. especially when using affibodies. In this sense, several examples reporting on affibodies and DARPins conjugated to nanomaterials have been published, demonstrating their suitability and feasibility in nanomedicine for cancer therapy. This minireview provides a survey of the most recent studies describing affibody- and DARPin-conjugated zero-dimensional nanomaterials, including inorganic, organic, and biological nanoparticles, nanorods, quantum dots, liposomes, and protein- and DNA-based assemblies for targeted cancer therapy in vitro and in vivo.

show abstract

Section: Hybrid Nanomaterialsmentioning

confidence: 91%

Section: Hybrid Nanomaterialsmentioning

confidence: 98%

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy

Gabriele,

Palerma,

Ippoliti

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…When stimulated by LIFU, MBs expand or contract, opening the tight junctions of the BBB/BTB and delivering drugs into brain tumors. 153 , 155 Several studies have reported that some drugs (eg, trastuzumab, 156 bevacizumab, 157 carboplatin, 158 , 159 temozolomide, 160 methotrexate, 161 and doxorubicin 162 ) can be delivered through the BTB using LIFU. Notably, LIFU has been demonstrated to have no significant side effects, and the pores or “windows” it forms on the BBB close within 6–8 h, preventing prolonged exposure and potential damage to neurons.…”

Section: Targeted Delivery Based On Mnpsmentioning

confidence: 99%

Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles

Xu,

Zhang,

Zhang

et al. 2023

IJN

View full text Add to dashboard Cite

Brain tumors, including primary gliomas and brain metastases, are one of the deadliest tumors because effective macromolecular antitumor drugs cannot easily penetrate the blood-brain barrier (BBB) and blood-brain tumor barrier (BTB). Magnetic nanoparticles (MNPs) are considered the most suitable nanocarriers for the delivery of brain tumor drugs because of their unique properties compared to other nanoparticles. Numerous preclinical and clinical studies have demonstrated the potential of these nanoparticles in magnetic targeting, nuclear magnetic resonance, magnetic thermal therapy, and ultrasonic hyperthermia. To further develop and optimize MNPs for the diagnosis and treatment of brain tumors, we attempt to outline recent advances in the use of MNPs to deliver drugs, with a particular focus on their efficacy in the delivery of anti-brain tumor drugs based on magnetic targeting and low-intensity focused ultrasound, magnetic resonance imaging for surgical real-time guidance, and magnetothermal and ultrasonic hyperthermia therapy. Furthermore, we summarize recent findings on the clinical application of MNPs and the research limitations that need to be addressed in clinical translation.

show abstract

Functionalization and magnetonavigation of T-lymphocytes functionalized via nanocomposite capsules targeting with electromagnetic tweezers

Abalymov,

Kurochkin,

German

et al. 2024

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Polymer/magnetite carriers functionalized by HER2-DARPin: Avoiding lysosomes during internalization and controlled toxicity of doxorubicin by focused ultrasound induced release

Cited by 4 publications

References 43 publications

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy

Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles

Functionalization and magnetonavigation of T-lymphocytes functionalized via nanocomposite capsules targeting with electromagnetic tweezers

Contact Info

Product

Resources

About